UVB-Induced MVP Release in Human Skin

Wright State University

Status and phase: Completed; Phase 1

Conditions: Microvesicle Particles; Ultraviolet B Radiation

Treatments: Dietary Supplement: Vitamin C; Dietary Supplement: Vitamin E

Study type: Interventional

Funder types: Other

Identifiers

NCT05734235

06201

Details and patient eligibility

About

This study is designed to assess if ultraviolet B radiation (UVB) found in sunlight causes the release of microvesicle particles in human skin, and if antioxidant vitamins can block their production.

Enrollment: 8 patients

Sex: Male

Ages: 21 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Male subjects
• Ages 21 to 45
• Skin type: Fitzpatrick Type I or II

Exclusion criteria

• Have underlying diseases that could affect wound healing
• On medications that are known photosensitizers (e.g., doxycycline) or anti-inflammatories (e.g., NSAIDS [except for low-dose aspirin] or steroids)
• History of abnormal scarring (e.g., keloids)
• Should not be on Vitamin C or E supplements for past month
• Unable to understand/complete informed consent
• Large volar arm tattoos that would inhibit the ability to conduct/evaluate the skin testing
• Renal compromise/kidney stones or allergy to Vitamin C/Vitamin E or lidocaine anaesthetic
• Use of tanning bends or recent UVB exposure to the areas in the past 3 months
• Recent (within 1 week) use to sunscreen to volar forearms

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

8 participants in 1 patient group

Vitamin C & Vitamin E

Experimental group

Description:

After subjects undergo UVB treatment then they will be instructed to take two Vitamin C and one Vitamin E tablets daily for 8 days.

Treatment:

Dietary Supplement: Vitamin C

Dietary Supplement: Vitamin E